CRA was retained in an international arbitration between two Japanese affiliates of multinational pharmaceutical companies. The dispute concerned Respondent’s performance under a co-promotion agreement. CRA’s team of life sciences consultants assessed indicators of commercially reasonable efforts using various industry data sources. The CRA team also quantified Claimant’s loss resulting from the alleged inadequate performance under the agreement, and responded to Respondent’s expert regarding damages alleged by Respondent.
Who bore the tariff burden? Economics of IEEPA refund disputes
The refund question sits at the intersection of customs procedure, administrative law, but also economics, and resolution will likely vary significantly across...